TURBT加吉西他滨膀胱灌注治疗浅表性膀胱癌的临床效果  

Clinical Effect of TURBT Plus Intravesical Instillation of Gemcitabine in the Treatment of Superficial Bladder Cancer

作　　者：朱彦 廖顺鸿 童宪楼 ZHU Yan;LIAO Shunhong;TONG Xianlou(Zigong Hospital of Traditional Chinese Medicine,Zigong,643010)

机构地区：[1]自贡市中医医院,643010

出　　处：《实用癌症杂志》2020年第10期1703-1706,共4页The Practical Journal of Cancer

摘　　要：目的探究尿道等离子电切术(TURBT)加吉西他滨膀胱灌注治疗浅表性膀胱癌的临床效果。方法选取浅表性膀胱癌患者82例,随机数表法分为2组,各41例。两组均由同一组医师进行TURBT治疗,观察组术后7 d给予吉西他滨膀胱灌注治疗,对照组术后7 d给予等量0.9%氯化钠溶液膀胱灌注。术后随访3年,记录两组术后1年、3年复发率、复发时间及并发症发生率,并于治疗前及治疗1年后抽取晨间空腹静脉血,检测可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)及肿瘤标志物水平。结果观察组术后1年、3年复发率均显著低于对照组,复发时间显著短于对照组,观察组并发症发生率显著低于对照组,差异有统计学意义(P<0.05);治疗后观察组血清sICAM-1、sVCAM-1水平及肿瘤标志物水平均显著低于对照组,差异有统计学意义(P<0.05)。结论TURBT加吉西他滨膀胱灌注治疗有助于降低浅表性膀胱癌治疗后复发率,延长患者生存时间,且毒副作用小,安全性较好,值得推广。Objective To investigate the clinical effects of transurethral resection bladder tumor(TURBT)plus intravesical instillation of gemcitabine in the treatment of superficial bladder cancer.Methods 82 patients with superficial bladder cancer were divided into 2 groups by the random number table method,41 cases in each group.The 2 groups were treated with TURBT performed by the same group of doctors.The observation group was treated with intravesical instillation of gemcitabine at 7 days after operation,while the control group was treated with equal volume of 0.9%sodium chloride solution.The patients were followed up for 3 years.The postoperative 1-year and 3-year recurrence rates,recurrence time and incidence of complications in the 2 groups were recorded.The fasting venous blood was collected before the treatment and after 1 year of treatment to detect levels of soluble intercellular adhesion molecule 1(sICAM-1),soluble vascular cell adhesion molecule-1(sVCAM-1)and tumor markers.Results Postoperative 1-year and 3-year recurrence rates of the observation group were significantly lower than those of the control group.The recurrence time was significantly shorter than that of the control group,and the incidence of complications in the observation group was significantly lower than that in the control group(P<0.05).Serum levels of sICAM-1 and sVCAM-1 and tumor markers were significantly lower in the observation group than in the control group after treatment(P<0.05).Conclusion TURBT plus intravesical instillation of gemcitabine can help to reduce the recurrence rate of superficial bladder cancer and prolong the survival time of patients with mild side effects and safety.

关 键 词：尿道等离子电切术 吉西他滨 浅表性膀胱癌 

分 类 号：R737.14[医药卫生—肿瘤]